In the present study we showed that PNPLA3 and TM6SF2 gene polymorphisms significantly increased the risk of advanced fibrosis in patients with NASH, while more importantly, IR increased the risk of advanced liver fibrosis in non-diabetic patients. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.